Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies

NCT03102320 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03102320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03102320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
May 26, 2017
Completion date
July 26, 2021
Enrollment
173 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms